Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring
NCT02679846 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1567
Last updated 2021-01-22
Summary
SAVE is a stratified cluster-randomised controlled, parallel group, open-label trial, with Epileptic Monitoring Unit (EMU) as the units of randomisation and patients as the unit of analysis.
The focus of research is the management of AntiEpileptic Drugs (AEDs) withdrawal during long term Video EEG (VEEG) monitoring in patients with drug resistant seizures. This non-standardised medical practice, which aims at promoting the occurrence of seizures during the time limit of the monitoring period, exposes patients to significant risks which should be minimised by harmonisation of practice and a standardised protocol of AEDs withdrawal.
SAVE will assess the impact of a standardised protocol of AEDs withdrawal during long-term VEEG monitoring on the frequency of seizure-related serious adverse events occurring during these monitorings and on the ability to obtain VEEG recording of seizures within appropriate time limits.
10 of the 22 EMUs will be randomised to the group where the standardised protocol of AEDs withdrawal will be used systematically, while the other ten EMUs will continue their current non-standardised practice of AEDs withdrawal, and will serve as a control group.
The setting of the study will include a 6 months evaluation phase, prior to randomisation, during which the organisational characteristics, baseline EMUs' activity, current management of AEDs withdrawal, and rate of Serious Adverse Events (SAEs) of each participating center will be evaluated.
The standardised study protocol of AEDs withdrawal has been defined on the basis of a systematic review of all relevant publications in the field.
Conditions
Interventions
- OTHER
-
Standardized protocol
The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Principal Investigators
-
Sylvain RHEIMS, MD · Service de Neurologie Fonctionnelle et d'Epileptologie et Institut des Epilepsies
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-19
- Primary Completion
- 2020-12-14
- Completion
- 2020-12-14
Countries
- France
Study Locations
More Related Trials
-
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
NCT01607346 ·Status: TERMINATED ·Phase: PHASE4
-
Assessment of Suicidality in Epilepsy - Rating Tools
NCT01085461 ·Status: COMPLETED
-
National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies
NCT02572297 ·Status: COMPLETED
-
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
NCT00887861 ·Status: COMPLETED ·Phase: PHASE2
-
Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00043914 ·Status: COMPLETED ·Phase: PHASE4
-
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611 ·Status: COMPLETED ·Phase: PHASE4
-
Comitial Prophylaxis in Neurosurgery in Patients Who Have Undergone Intracranial Surgery Programmed Supratentorial Surgery (Exeresis or Biopsy) Between 2019 and 2022
NCT05670860 ·Status: UNKNOWN
-
Impact of Pharmaceutical Interviews on the Medication Adherence of Epileptic Patients
NCT04876820 ·Status: TERMINATED ·Phase: NA
-
Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures
NCT01227902 ·Status: COMPLETED ·Phase: PHASE3
-
Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY
NCT03419000 ·Status: COMPLETED ·Phase: NA
-
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
NCT02161185 ·Status: TERMINATED ·Phase: PHASE3
-
A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
NCT02582866 ·Status: COMPLETED ·Phase: PHASE3
-
Placebo Optimization of the Presurgical Long-term Video-EEG Monitoring
NCT06383689 ·Status: RECRUITING ·Phase: NA
-
Evaluation of the 24/7 EEG™ SubQ System in Subjects With Uncontrolled Genetic Generalised Epilepsy Syndrome
NCT05241678 ·Status: COMPLETED
-
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NCT02495844 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Predictors of Response to Anti Epilepsy in Epilepsy
NCT02883712 ·Status: TERMINATED
-
Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study
NCT02100644 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial of Generic Substitution of Antiepileptic Drugs
NCT02429596 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
NCT04252846 ·Status: COMPLETED
-
The Efficacy and Safety of Minocycline in the Treatment of Drug-resistant Epilepsy in NORSE Patients
NCT05958069 ·Status: UNKNOWN ·Phase: NA
-
The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
NCT00807989 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
NCT02427607 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT00150293 ·Status: COMPLETED ·Phase: PHASE3
-
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
NCT05697614 ·Status: UNKNOWN ·Phase: PHASE4
-
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
NCT00144690 ·Status: COMPLETED ·Phase: PHASE2